EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
From Hallucinations to Evidence: LLMs clinicians can finally trust
Research Fellow, Institute of Health Informatics, University College London
Jinge Wu is a Research Fellow at the UCL Institute of Health Informatics specialising in multimodal large language models for clinical decision support and medical AI She has led research projects funded by UKRI MRC and Health Data Research UK working with largescale NHS electronic health record data to develop capable reliable and explainable AI for realworld clinical applications Her research ha...
Articles
The Green Revolution in Medicine
The term Green Revolution originally referred to the agricultural transformation of the s when scientific advances dramatically increased food production and reshaped global food security That revolution changed the world by solving a critical human challenge hunger Yet today humanity faces a new crisis that is equally
Research Insights
Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient
Abstract Objective To develop and validate an instrument to assess adherence to each individual drug taken by patients undergoing longterm treatment Design Multicentre prospective observational validation study
Case Studies
Labile Biologics - Stable Aqueous Formulation of Recombinant Factor VIII
Challenge All marketed Factor VIII products are lyophilised preparations produced by either recombinant technology or purified from pooled plasma The preparations are typically stabilised by addition of sugars Administration of the lyophilised product is a very complex procedure involving a number
Techno Trends
Arizon State University Discovered First-of-its-kind DNA Nano-engine
A novel type of nanoengine made of DNA has been developed by an international team of scientistsIt operates through a clever mechanism and is capable of executing pulsing movements The researchers are currently in the planning stages of equipping
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Role of Bioinformatics in Accelerating Translational Research
Vasundhara Dauneria is a biotechnology professional with over six years of experience spanning genomics, next-generation sequencing, and bioinformatics. She has worked across wet-lab and computational research environments, with hands-on expertise in NGS workflows, assay development, and multi-omics data analysis. Her work focuses on applying data-driven approaches to support translational research and precision medicine initiatives.
Nanotechnology based Drug Delivery for Infectious Diseases
Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.
Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients
Dr. Ikram Khan, the first author of the Article, Studying Medical Microbiology in Lanzhou University China as a PhD student, and working on blood microbial Ecology and their association with cardiovascular disease. In March 2022, we published two Articles on this work. Email: ikram2018@lzu.edu.cn
Assistant Professor Imran Khan, 2nd Author of this article, Supervises BS(Hons) students and is engaged in the teaching and research of Bacteriology, Nano-medicine, and Molecular Biology. Presently working as, a member of Quality Enhancement Cell at Xcito School of Nursing and Allied Health Sciences Pakistan. Email:Imran.mic727@gmail.com
Professor Zhou Jianye, is also Co-supervisor of this study, and supervises Master students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology at School of Northwest Minzu University”.Email: 14092785@qq.com
Professor Xie Ping, supervises Master and PhD students.She has long been engaged in the research of cardiovascular disease pathogenesis and drug prevention. Her current status is “Director of Cardiovascular Center of Gansu Provincial Hospital”.
Professor Li Zhiqiang, is a Co-supervisor of this study, and supervises Master and PhD students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology. His current status is “Director of graduate School of Northwest Minzu University”. Email: Lizhiqiang6767@163.com
Professor An Lizhe, supervise this work as a First Supervisor. He supervises PhD and doctoral students, and engaged in the Teaching and Research of Molecular Biology, Environmental Botany and Ecology. Currently working as, a President and Deputy Secretary of the Party Committee of Beijing Forestry University. Email: yxlzq@xbmu.edu.cn
Dr. Zhang Xiaowei is a professor, chief physician, director of the second ward of cardiovascular medicine, and deputy director of the Science and Technology Department. He has completed projects such as epidemiological investigation and prevention plan research of hypertension in Gansu Province and has published many SCI and CSCD papers, and currently undertakes 1st national natural science foundation, 2nd provincial natural science foundations, and 1st municipal science foundation.
Combating the FWA Menace
Ravi Iyer is a visionary and innovative executive with diverse experience in leading and managing product delivery, client implementation, customer service, and operations with direct responsibility for multimillion-dollar budgets. He has extensive experience delivering across multiple disciplines, including Data Management, Data Governance, Cloud Architecture, Advanced Analytics, Master Data Management, Digital Products, and Digital Transformation. Excellent communicator who works collaboratively to deliver technology strategies and value added solutions that meet the needs of all business functions. Ravi is currently the technology executive and Senior Director at Elevance Health Inc.
Narasimha is result driven leader with vast experience in executing various PBM, Health care, Financial, and securities trading applications. Technical expertise in Big data, Cloud, Analytics, Mainframe, BPM, testing, and Data warehouse projects at esteemed organizations like Anthem, Tetrasoft, DST, HCL, Deutsche bank, and Atos Origin. He currently works as Solution Architect at Tetrasoft Inc. Narasimha has vast experience in Pre-sales, Project management, effective customer communication, Architect, Technical Lead, On-site coordinator, and business Analyst roles for various complex assignments across the globe.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
press releasesRead more...
Beyond Annex 1: PDA Aseptic Processing of Biopharmaceuticals Conference 2026 Explores the Future of Sterility Assurance
The Parenteral Drug Association PDA Asia Pacific will host the PDA Aseptic Processing of Biopharmaceuticals Conference on November at the Sheraton Grand Incheon Hotel in Incheon South Korea
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
AstraZenecas ETCAMAH camizestrant in combination with a cyclindependent kinase CDK inhibitor abemaciclib palbociclib or ribociclib has been approved in the US for the treatment of adult patients
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
Researchers Gain Faster Access to Complex DNA as Integrated DNA Technologies and Ansa Biotechnologies Expand Ordering Platform
Integrated DNA Technologies IDT a Danaher company and a global leader in genomics and Ansa Biotechnologies Inc a trusted partner for DNA synthesis today announced an expansion of their partnership
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience
Biocytogen Pharmaceuticals Beijing Co Ltd Biocytogen SSE HKEX today announced that it has entered into a nonexclusive licensing agreement with Qilu Pharmaceutical Co Ltd
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma AG FSE HPHA a clinicalstage biotech company developing innovative Antibody Drug Conjugates ADCs today announced that its whollyowned subsidiary Heidelberg Pharma Research
EventsRead more...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
14 - 16
Sep 202615 - 17
Sep 2026COPD Drug Development Summit 2026
Street, Boston, MA 02210, USA
21 - 23
Sep 2026Cell & Gene Therapy World Conference
Miami, Florida, USA
21 - 23
Sep 2026Cancer R&D World Conference
Hilton Garden Inn Miami Dolphi...
22 - 23
Sep 2026PDA Advanced Parenteral Therapeutics & Quality Summit
Illume Hotel Taipei, Taiwan
22 - 24
Sep 2026InsurInnovator Connect Asia
Singapore
28 - 01
Sep 2026Discovery on Target 2026
Boston, MA, USA
LATEST NEWSRead more...
ZANVASTRO approved by FDA as first disease-modifying treatment for Alexander disease
Ionis Pharmaceuticals has received approval from the US Food and Drug Administration FDA for ZANVASTRO zilganersen to treat Alexander disease AxD in paediatric and adult patients
Global Experts to Gather in Osaka for PDA Aseptic Manufacturing and Regulatory Science Symposium 2026
As pharmaceutical manufacturers worldwide continue to navigate the implementation of PICS GMP Annex a landmark international symposium in Japan will bring together regulators industry leaders
HUTCHMED Enters into Agreement with GSK for Novel KRAS-EGFR Cancer Therapy
HUTCHMED has entered into an exclusive development and licensing agreement with GSK for HMPLA an investigational antibodytargeted therapy conjugate ATTC designed to target KRAS and EGFR in solid tumours
Everest Medicines Receives Approval for CARDAMYST to Treat Acute PSVT
Everest Medicines has received approval from Chinas National Medical Products Administration NMPA for CARDAMYST etripamil nasal spray for the conversion of acute symptomatic episodes
HUTCHMED Announces Approval of ATLED® (Fanregratinib) for FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
HUTCHMED has received conditional approval from Chinas National Medical Products Administration NMPA for ATLED fanregratinib to treat adults with advanced metastatic or unresectable intrahepatic cholangiocarcinoma ICC with FGFR fusion or rearrangement who have previously received systemic therapy
Osivax Enters into Collaboration with GC Biopharma to Develop Next-Generation Influenza Vaccine
Osivax and GC Biopharma have entered into a strategic collaboration to develop and commercialise a nextgeneration seasonal influenza vaccine designed to provide broader and more durable protection against a range of influenza strains